Bal Pharma Ltd

NSE
BALPHARMA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Bal Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
48.10% Gain from 52W Low
18
TTM PE Ratio
Below industry Median
25.7
Price to Book Ratio
Below industry Median
2.7
Dividend yield 1yr %
Above industry Median
0.8
TTM PEG Ratio
PEG TTM is less than 1
0.1
RSI
RSI is mid-range
56.3
MFI
MFI is mid-range
52.8

Bal Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Bal Pharma Ltd shareholding Pattern

Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%
Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%
Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%
Promoter
51.6%
Foreign Institutions
0.1%
Public
48.2%
Promoter
51.6%
Foreign Institutions
0.2%
Public
48.2%
Promoter
51.6%
Foreign Institutions
0.2%
Public
48.2%

Bal Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
11
Bearish Moving Averages
5
5Day EMA
121.30
10Day EMA
120.90
12Day EMA
120.70
20Day EMA
119.30
26Day EMA
118.10
50Day EMA
114.20
100Day EMA
110.40
200Day EMA
106.10
5Day SMA
121.80
10Day SMA
121.30
20Day SMA
119.80
30Day SMA
118.20
50Day SMA
111.80
100Day SMA
107.80
150Day SMA
109.20
200Day SMA
105.90
Delivery & Volume
Resistance & Support
121.07
Pivot
Resistance
First Resistance
124.14
Second Resistance
128.01
Third Resistance
131.08
Support
First Support
117.20
Second support
114.13
Third Support
110.26
Relative Strength Index
56.26
Money Flow Index
52.79
MACD
2.54
MACD Signal
2.92
Average True Range
5.10
Average Directional Index
28.13
Rate of Change (21)
-0.43
Rate of Change (125)
5.91
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Bafna Pharmaceuticals Ltd.
216.08
73.25
119
Krebs Biochemicals & Industries Ltd.
180.72
60.35
93.95
BDH Industries Ltd.
-
-
-
Smruthi Organics Ltd.
-
-
-
Vaishali Pharma Ltd.
167.68
114.85
203.6
Sotac Pharmaceuticals Ltd
-
-
-

Bal Pharma Ltd Company background

Founded in: 1987
Managing director: Shailesh Siroya
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 87. In Mar.90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 199798, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The companys product range has been expanded with the introduction of AZIWIN, CAFIMOL CORTIDERM.The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium M, Progit MPS in its ethical division during 19992000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named SERVETUS has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 201415 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 201617, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 201718, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drugsmanufacturing unit at Yadgir District , Karnataka in year 202223. It launched Sitagliptin (a DPP4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND SITABENDM, respectively in 2023.
Read More

Bal Pharma Ltd FAQs

Bal Pharma Ltd shares are currently priced at 120.26 on NSE and 120.9 on BSE as of 7/11/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Bal Pharma Ltd [BALPHARMA] share was 25.46. The Bal Pharma Ltd [BALPHARMA] share hit a 1-year low of Rs. 81.2 and a 1-year high of Rs. 132.45.

The market cap of Bal Pharma Ltd is Rs. 190.06 Cr. as of 7/11/2024 12:00:00 AM.

The PE ratios of Bal Pharma Ltd is 18.6 as of 7/11/2024 12:00:00 AM.

The PB ratios of Bal Pharma Ltd is 1.8 as of 7/11/2024 12:00:00 AM

You can easily buy Bal Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -